Conditions: Chronic Plaque Psoriasis
Keywords: Psoriasis, inflammatory skin disease, scaly patches Psoriasis inflammatory skin disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1306
Healthy volunteers: no

Brief summary:
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.

Detailed description:

Arms:
arm 1: AIN457 150mg arm 2: AIN457 300mg arm 3: Placebo arm 4: Etanercept arm 5: Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase arm 6: Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase

Interventions: intervention 1: Placebo intervention 2: secukinumab (AIN457) intervention 3: etanercept
Intervention descriptions: intervention 1: Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept intervention 2: secukinumab (AIN457) 150mg or 300mg subcutaneous intervention 3: etanercept 50mg subcutaneous

Protocol document: